Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saroglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 18/20 | 0.56 |
| ▸ | PPARA known ✓ | Q07869 | 18/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saroglitazar SCHEMBL21048447 | 1.00 | PGR (0.98) | PGRADORA3CHRM1TBXA2RPTGS1 | |
| Saroglitazar SCHEMBL12472346 | 0.99 | PGR (1.00) | PGRADORA3CHRM1TBXA2RPTGS1 | |
| Saroglitazar SCHEMBL16346340 | 0.99 | PGR (1.00) | PGRADORA3CHRM1TBXA2RPTGS1 | |
| Saroglitazar SCHEMBL22410880 | 0.98 | PGR (0.98) | PGRADORA3CHRM1TBXA2RPTGS1 | |
| Saroglitazar SCHEMBL22410886 | 0.98 | PGR (0.98) | PGRADORA3CHRM1TBXA2RPTGS1 | |
| Saroglitazar SCHEMBL22410740 | 0.98 | PGR (0.98) | PGRADORA3CHRM1TBXA2RPTGS1 | |
| Saroglitazar SCHEMBL22410898 | 0.98 | PGR (0.98) | PGRADORA3CHRM1TBXA2RPTGS1 | |
| Saroglitazar SCHEMBL22410884 | 0.98 | PGR (0.98) | PGRADORA3CHRM1TBXA2RPTGS1 | |
| Saroglitazar SCHEMBL22410857 | 0.98 | PGR (0.98) | PGRADORA3CHRM1TBXA2RPTGS1 | |
| Saroglitazar SCHEMBL21048454 | 0.98 | PGR (0.98) | PGRADORA3CHRM1TBXA2RPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10315993-B2 | Synergistic compositions | CADILA HEALTHCARE LIMITED (IN) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10315993-B2 | Synergistic compositions | DPP4, DPP7, PPARD | PPARG 6/4885PPARA 5/4885PGR 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.